Springer Protocols: Abstract: 10. Dendritic Cells in Clinical Trials for Multiple Myeloma

10. Dendritic Cells in Clinical Trials for Multiple Myeloma

By: Volker L³, Reichardt Peter Brossart

Abstract

Full Text

Download PDF (105K)

Due to the existence of the truly specific tumor antigen idiotype in multiple myeloma and based on encouraging data from dendritic cell vaccinated B-cell non-Hodgkin’s lymphoma (NHL) patients, dendritic cell-based vaccination was first initiated in myeloma patients in 1995. This overview will summarize published and ongoing clinical trials in patients with multiple myeloma who are treated with idiotype-based dendritic cell (Id/DC) vaccination. All groups of investigators have found that Id/DC vaccination of multiple-myeloma patients is feasible and that myeloma-specific immunity can be induced in heavily pretreated individuals. In future trials, new dendritic cell-based immunization strategies will be investigated based on techniques like RNA transfection of DC.

Affiliation(s): (3) Department of Hematology, Oncology, Immunology, and Rheumatology, University of Tübingen, Tübingen, Germany

Book Title: Adoptive Immunotherapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 109 | Pub. Date: Nov-30-2004 | Page Range: 127-135 | DOI: 10.1385/1-59259-862-5:127

Subject: Immunology

Key Words: Dendritic cells - immunotherapy - multiple myeloma - clinical trial - idiotype - T-cells

References

Download References

1.	Attal, M., Harousseau, J. L., Stoppa, A. M., et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335 91–97.

2.	Child, J. A., Morgan, G. J., Davies, F. E., et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875–1883.

3.	Singhal, S., Mehta, J., Desikan, R., et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341, 1565–1571.

4.	Richardson, P. (2003) Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat. Rev. 29(Suppl. 1) 33–39.

5.	Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S., and Eisen, H. N. (1972) Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540–1544.

6.	Pellat-Deceunynck, C. (2003) Tumour-associated antigens in multiple myeloma. Br. J. Haematol. 120, 3–9.

7.	van Baren, N., Brasseur, F., Godelaine, D., et al. (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94, 1156–1164.

8.	Brossart, P., Schneider, A., Dill, P., et al. (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61, 6846–6850.

9.	Chiriva-Internati, M., Wang, Z., Salati, E., Bumm, K., Barlogie, B., and Lim, S. H. (2002) Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 100, 961–965.

10.	Tureci, O., Sahin, U., and Pfreundschuh, M. (1997) Serological analysis of human tumor antigens: molecular definition and implications. Mol. Med. Today 3, 342–349.

11.	Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., Miller, R. A., and Levy, R. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209–1215.

12.	Hsu, F. J., Caspar, C. B., Czerwinski, D., et al. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89, 3129–3135.

13.	Bendandi, M., Gocke, C. D., Kobrin, C. B., et al. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5, 1171–1177.

14.	Bergenbrant, S., Yi, Q., Osterborg, A., et al. (1996) Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br. J. Haematol. 92, 840–846.

15.	Osterborg, A., Yi, Q., Henriksson, L., et al. (1998) Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood 91, 2459–2466.

16.	Massaia, M., Borrione, P., Battaglio, et al. (1999) Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94, 673–683.

17.	Reichardt, V. L., Okada, C. Y., Stockerl-Goldstein, K. E., Bogen, B., and Levy, R. (1997) Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol. Blood Marrow Transplant. 3, 157–163.

18.	Hsu, F. J., Benike, C., Fagnoni, F., et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52–58.

19.	Timmerman, J. M., Czerwinski, D. K., Davis, T. A., et al. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517–1526.

20.	Reichardt, V. L., Okada, C. Y., Liso, A., et al. (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93, 2411–2419.

21.	Raje, N., Gong, J., Chauhan, D., et al. (1999) Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi’s sarcoma herpesvirus gene sequences. Blood 93, 1487–1495.

22.	Brown, R. D., Pope, B., Murray, A., et al. (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98, 2992–2998.

23.	Ratta, M., Fagnoni, F., Curti, A., et al. (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100, 230–237.

24.	Wen, Y. J., Ling, M., Bailey-Wood, R., and Lim, S. H. (1998) Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 4,957–962.

25.	Ratta, M., Curti, A., Fogli, M., et al. (2000) Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients. Exp. Hematol. 28, 931–940.

26.	Titzer, S., Christensen, O., Manzke, O., et al. (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br. J. Haematol. 108,805–816.

27.	Tarte, K., Lu, Z. Y., Fiol, G., Legouffe, E., Rossi, J. F., and Klein, B. (1997) Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood 90, 3482–3495.

28.	Butch, A. W., Kelly, K. A., and Munshi, N. C. (2001) Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein. Exp. Hematol. 29, 85–92.

29.	Tarte, K., Fiol, G., Rossi, J. F., and Klein, B. (2000) Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia 14, 2182–2192.

30.	Reichardt, V.L., Milazzo, C., Brugger, W., Einsele, H., Kanz, L, and Brossart, P. (2003) Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 88,1139–1149.

31.	Reichardt, V., Okada, C., Benike, C., et al. (1996) Idiotypic vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood 88 (Suppl 1), 481a.

32.	Liso, A., Stockerl-Goldstein, K. E., Auffermann-Gretzinger, S., et al. (2000). Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6, 621–627.

33.	Lim, S. H. and Bailey-Wood, R. (1999) Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 83, 215–222.

34.	Cull, G., Durrant, L., Stainer, C., Haynes, A., and Russell, N. (1999) Generation of antiidiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br. J. Haematol. 107, 648–655.

35.	Yi, Q., Desikan, R., Barlogie, B., and Munshi, N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br. J. Haematol. 117, 297–305.

36.	Wen, Y. J., Min, R., Tricot, G., Barlogie, B., and Yi, Q. (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99, 3280–3285.

37.	Fagerberg, J., Yi, Q., Gigliotti, D., et al. (1999) T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int. J. Cancer 80, 671–680.

38.	Hansson, L., Rabbani, H., Fagerberg, J., Osterborg, A., and Mellstedt, H. (2003) T-cell epitopes within the complementarity-determining and framework regions of the tumorderived immunoglobulin heavy chain in multiple myeloma. Blood 101, 4930–4936.

39.	Trojan, A., Schultze, J. L., Witzens, M., et al. (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat. Med. 6, 667–672.

40.	Gong, J., Koido, S., Chen, D., et al. (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmocytoma cells is potentiated by interleukin 12. Blood 99, 2512–2517.

41.	Milazzo, C., Reichardt, V. L., Muller, M. R., Grunebach, F., and Brossart, P. (2003) Induction of myeloma specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101, 977–982.

Comments (Loading...)

Post comment/View all comments